{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:14:23Z","timestamp":1778901263305,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008131","name":"Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"BMBF Bonn","doi-asserted-by":"publisher","award":["01EO2107"],"award-info":[{"award-number":["01EO2107"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","award":["EXC2151\\u2013390873048"],"award-info":[{"award-number":["EXC2151\\u2013390873048"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2020_EKEA.129"],"award-info":[{"award-number":["2020_EKEA.129"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.euo.2023.11.005","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:59:49Z","timestamp":1700675989000},"page":"328-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy"],"prefix":"10.1016","volume":"7","author":[{"given":"Jonas","family":"Saal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Bald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"H\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3258-0586","authenticated-orcid":false,"given":"Niklas","family":"Kl\u00fcmper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.11.005_b0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2023.11.005_b0010","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.annonc.2022.04.450","article-title":"Deciphering radiological stable disease to immune checkpoint inhibitors","volume":"33","author":"Luo","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2023.11.005_b0015","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamaoncol.2023.1822","article-title":"Integrating on-treatment modified Glasgow Prognostic Score and imaging to predict response and outcomes in metastatic renal cell carcinoma","volume":"9","author":"Saal","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2023.11.005_b0020","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.bjc.6606087","article-title":"An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome study","volume":"104","author":"Proctor","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2023.11.005_b0025","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41571-023-00734-5","article-title":"Cancer-associated cachexia \u2014 understanding the tumour macroenvironment and microenvironment to improve management","volume":"20","author":"Argil\u00e9s","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.euo.2023.11.005_b0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ccell.2023.02.007","article-title":"Cancer cachexia: involvement of an expanding macroenvironment","volume":"41","author":"Pryce","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2023.11.005_b0035","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.eururo.2023.06.003","article-title":"Oligometastatic bladder cancer: defining a novel entity","volume":"84","author":"Labaki","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.11.005_b0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004849","article-title":"iRECIST and atypical patterns of response to immuno-oncology drugs","volume":"10","author":"Ramon-Patino","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2023.11.005_b0045","article-title":"Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations","volume":"3","author":"Hu","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2023.11.005_b0050","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nrd.2016.233","article-title":"Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity","volume":"16","author":"Lesterhuis","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.euo.2023.11.005_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004024","article-title":"C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer","volume":"10","author":"Kl\u00fcmper","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2023.11.005_b0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejca.2022.02.022","article-title":"C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma","volume":"167","author":"Kl\u00fcmper","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2023.11.005_b0065","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad027","article-title":"Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial","volume":"7","author":"Saal","year":"2023","journal-title":"JNCI Cancer Spectr"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112300250X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112300250X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:34:23Z","timestamp":1778898863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112300250X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S258893112300250X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.11.005","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}